Cargando…
Phase 2 Multi-institutional Trial Evaluating Gemcitabine and Stereotactic Body Radiotherapy for Patients With Locally Advanced Unresectable Pancreatic Adenocarcinoma
BACKGROUND: This phase 2 multi-institutional study was designed to determine whether gemcitabine (GEM) with fractionated stereotactic body radiotherapy (SBRT) results in acceptable late grade 2 to 4 gastrointestinal toxicity when compared with a prior trial of GEM with single-fraction SBRT in patien...
Autores principales: | Herman, Joseph M, Chang, Daniel T, Goodman, Karyn A, Dholakia, Avani S, Raman, Siva P, Hacker-Prietz, Amy, Iacobuzio-Donahue, Christine A, Griffith, Mary E, Pawlik, Timothy M, Pai, Jonathan S, O'Reilly, Eileen, Fisher, George A, Wild, Aaron T, Rosati, Lauren M, Zheng, Lei, Wolfgang, Christopher L, Laheru, Daniel A, Columbo, Laurie A, Sugar, Elizabeth A, Koong, Albert C |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BlackWell Publishing Ltd
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4368473/ https://www.ncbi.nlm.nih.gov/pubmed/25538019 http://dx.doi.org/10.1002/cncr.29161 |
Ejemplares similares
-
Galunisertib plus gemcitabine vs. gemcitabine for first-line treatment of patients with unresectable pancreatic cancer
por: Melisi, Davide, et al.
Publicado: (2018) -
Gemcitabine and docetaxel in relapsed and unresectable high-grade osteosarcoma and spindle cell sarcoma of bone
por: Palmerini, E., et al.
Publicado: (2016) -
What Advanced Practitioners Need to Know About the Diagnosis and Treatment of Patients With Pancreatic Cancer
por: Herman, Joseph M., et al.
Publicado: (2017) -
Phase 2 study of vismodegib, a hedgehog inhibitor, combined with gemcitabine and nab-paclitaxel in patients with untreated metastatic pancreatic adenocarcinoma
por: De Jesus-Acosta, Ana, et al.
Publicado: (2019) -
Neoadjuvant Stereotactic Body Radiotherapy After Upfront Chemotherapy Improves Pathologic Outcomes Compared With Chemotherapy Alone for Patients With Borderline Resectable or Locally Advanced Pancreatic Adenocarcinoma Without Increasing Perioperative Toxicity
por: Hill, Colin S., et al.
Publicado: (2022)